Group 1 - The article discusses a series of online meetings scheduled for March 2023, focusing on various sectors including pharmaceuticals, agriculture, new energy, and chemicals [24]. - The first meeting on March 23, 2023, at 19:00, will cover a deep report on Zai Ding Pharmaceutical, presented by the chief analyst and an analyst from the pharmaceutical sector [24]. - The second meeting on March 23, 2023, at 20:00, will focus on investment strategies in the planting sector, led by the chief agricultural analyst and an agricultural analyst [24]. Group 2 - A meeting on March 25, 2023, at 20:30, will explore new opportunities in the new energy sector, specifically the seventh series of discussions, presented by the vice president and chief analyst of the electric new energy sector [24]. - On March 27, 2023, at 11:00, a session titled "Europe's Risks, China's Opportunities" will address the impact of natural gas supply shocks on the vitamin industry, led by a chemical industry analyst [24]. - The final meeting on March 27, 2023, at 15:00, will provide insights into the electronic industry for April, presented by the chief analyst of the electronic sector [24].

Group 1 - The core viewpoint of the news is the appointment of Zhang Xue and Li Huiyao as co-heads of the pharmaceutical and biotechnology research team at Guosheng Securities, indicating a strategic move to strengthen their research capabilities in the pharmaceutical sector [1] - Zhang Xue has a Master's degree in Public Health from Peking University and possesses a dual background in medicine and finance, with 8 years of experience in pharmaceutical research, previously working at Chuan Cai Securities, Xinda Securities, and Tianfeng Securities [1] - Li Huiyao holds a PhD in Medicine from Sun Yat-sen University and has 6 years of experience in pharmaceutical research, having worked at Xinda Securities and Tianfeng Securities [1] Group 2 - The recruitment of multiple analysts, including two co-heads for the pharmaceutical sector, reflects Guosheng Securities' commitment to expanding its research team and enhancing its analytical capabilities in the healthcare industry [1] - The article also mentions another analyst, who has a Master's degree in Management from Shanghai Jiao Tong University and 4 years of experience in pharmaceutical research, focusing on traditional Chinese medicine, pharmacies, and distribution [8] - Additionally, a research assistant with a Bachelor's degree in Biotechnology from Wuhan University and a Master's in Biomedical Engineering from the National University of Singapore is part of the team, concentrating on innovative drug research and clinical progress [10]